Table 2 Study Discontinuations and Benzodiazepine Use, by Treatment Group and Time Period
Days 1 to 7 | Days 8 to 36 | |||||
|---|---|---|---|---|---|---|
Placebo (n = 160) | Paliperidone palmitate 234 mg (n = 476) | Placebo (n = 160) | Paliperidone palmitate 39 mg (n = 155) | Paliperidone palmitate 156 mg (n = 161) | Paliperidone palmitate 234 mg (n = 160) | |
Discontinuations, No., (%) | 7 (4.4%) | 14 (2.9%) | 52 (32.5%) | 38 (24.5%) | 38 (23.6%) | 32 (20.0%) |
Discontinuation Reason, No., (%) | ||||||
Lack of efficacy | 2 (1.3%) | 3 (0.6%) | 29 (18.1%) | 14 (9.0%) | 14 (8.7%) | 16 (10.0%) |
Withdrawal of consent | 3 (1.9%) | 5 (1.1%) | 12 (7.5%) | 12 (7.7%) | 17 (10.6%) | 10 (6.3%) |
Adverse event | 2 (1.3%) | 4 (0.8%) | 5 (3.1%) | 8 (5.2%) | 5 (3.1%) | 5 (3.1%) |
Lost to follow-up | 0 | 0 | 6 (3.8%) | 4 (2.6%) | 1 (0.6%) | 1 (0.6%) |
Other | 0 | 2(0.4%) | 0 | 0 | 1 (0.6%) | 0 |
Benzodiazepine Use, No. (%) | 80 (50%) | 247 (51.9%) | 70 (43.8%) | 66 (42.6%) | 54 (33.5%) | 64 (40.0%) |